Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard) (“Formycon” or “the Company”) today provided an update on key developments across various biosimilar projects and invites ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

MiscellaneousFormycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27 CET/CESTThe issuer is solely responsible for the content of ...

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

PYX-201, an antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets ...

Known internationally as Merck Sharp & Dohme (MSD), the company is ... and in line with expectations. Keytruda remains the company’s primary driver of growth, with revenue increasing by 17% ...

Known internationally as Merck Sharp & Dohme (MSD), the company is ... and in line with expectations. Keytruda remains the company’s primary driver of growth, with revenue increasing by 17% ...